0.0996  0.049 (94.91%)		10-29 16:00
Open: 0.08 High: 0.0996 Volume: 418		Pre. Close: 0.0511 Low: 0.08 Market Cap: 4(M)

Short term
Mid term
Targets	6-month :	1.26	1-year :	1.57
Resists	First :	1.08	Second :	1.35
Pivot price	0.91
Supports	First :	0.64	Second :	0.54
MAs	MA(5) :	0.79	MA(20) :	0.98
	MA(100) :	1.49	MA(250) :	2.27
MACD	MACD :	-0.2	Signal :	-0.2
%K %D	K(14,3) :	15.2	D(3) :	20
RSI	RSI(14): 34.6
52-week	High :	7.19	Low :	0.05

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ADXS ] has closed above bottom band by 16.8%. Bollinger Bands are 24.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.85 - 0.86	0.86 - 0.86
Low:	0.68 - 0.69	0.69 - 0.69
Close:	0.71 - 0.72	0.72 - 0.73

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

Wed, 09 Apr 2025
OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals - Business Wire

Wed, 29 Jan 2025
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline - Business Wire

Thu, 09 May 2024
Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations - Yahoo Finance

Thu, 19 Oct 2023
Ayala Pharmaceuticals Announces Closing of Merger with Biosight - GlobeNewswire

Fri, 20 Jan 2023
Advaxis completes merger to become Ayala Pharmaceuticals - NJBIZ

Thu, 19 Jan 2023
Advaxis and Ayala Pharmaceuticals Complete Merger - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: OTC
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	5 (M)
Held by Insiders	1.49e+007 (%)
Held by Institutions	0 (%)
Shares Short	45 (K)
Shares Short P.Month	0 (K)

EPS	-3.734e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-5 %
Return on Assets (ttm)	419.5 %
Return on Equity (ttm)	-95.9 %
Qtrly Rev. Growth	692000 %
Gross Profit (p.s.)	-42.92
Sales Per Share	-81.34
EBITDA (p.s.)	0
Qtrly Earnings Growth	-7.9 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-35 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.01
Price to Cash Flow	-0

Dividend	0
Forward Dividend	39890
Dividend Yield	0%
Dividend Pay Date	2019-03-28
Ex-Dividend Date	Invalid DateTime.